This session will open with a Time=Lives Talk by Sandra Abrevaya and Brian Wallach, Co-Founders of I AM ALS, followed by a panel discussion on Value-based Payment Models.

Value-based payment has long been viewed as a key approach to facilitating access while ensuring accountability for costs and quality. But when it comes to transformative technologies, such as gene therapies that carry price tags much higher than conventional therapies, are value-based payment models still the right approach? In this session, experts will discuss successes and challenges of implementing value-based payment. They will further explore how models are evolving to accommodate gene therapies.

Guests

Sandra Abrevaya
Co-Founder and CEO, Synapticure; Co-Founder, I AM ALS

Brian Wallach
Co-Founder and Board Chair, Synapticure; Co-Founder, I AM ALS

Moderator

Aneesh Chopra
President, CareJourney

Speakers

Lee Fleisher
Chief Medical Officer and Director, Center for Clinical Standards and Quality, Centers for Medicare & Medicaid Services

Maia Z. Laing
Patient Advocate, Zakara Inc.

Hoangmai Pham
Founder and President, Institute for Exceptional Care

Jack Rollins
Director of Federal Policy, National Association of Medicaid Directors